{"nctId":"NCT04228445","briefTitle":"3,3'-Dioxo-2,2'-Bisindolylidene-5,5'-Disulfonate Disodium 0.8% Solution as an Aid for Ureteral Patency","startDateStruct":{"date":"2020-02-13","type":"ACTUAL"},"conditions":["Ureter Injury"],"count":121,"armGroups":[{"label":"HIGH DOSE","type":"EXPERIMENTAL","interventionNames":["Drug: 3,3'-Dioxo-2,2'-bisindolylidene-5,5'-disulfonate disodium 0.8%","Drug: Saline spray"]},{"label":"LOW DOSE","type":"EXPERIMENTAL","interventionNames":["Drug: 3,3'-Dioxo-2,2'-bisindolylidene-5,5'-disulfonate disodium 0.8%","Drug: Saline spray"]},{"label":"Saline","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Saline spray"]}],"interventions":[{"name":"3,3'-Dioxo-2,2'-bisindolylidene-5,5'-disulfonate disodium 0.8%","otherNames":[]},{"name":"Saline spray","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects between ≥ 18 and ≤ 85 years old.\n* Subjects who signed written, IRB approved, informed consent form.\n* Subjects scheduled for urological or gynecological surgical procedures in which the patency of the ureter must be assessed by the surgeon during the procedure\n\nExclusion Criteria:\n\n* Subjects with stage 4 or 5 Chronic Kidney Failure as evidenced by a GFR \\<30 mL/min/1.73m2 (using the MDRD) or need for dialysis in the near future, or having only 1 kidney.\n* Subjects with known severe hypersensitivity reactions to IC or other dyes including contrast agents.\n* Known history of drug or alcohol abuse within 6 months prior to the time of screening visit.\n* Subjects, as assessed by the Investigator, with conditions/concomitant diseases precluding their safe participation in this study (e.g. major systemic diseases).\n* Unable to meet specific protocol requirements (e.g., scheduled visits) or subject is uncooperative or has a condition that could lead to non-compliance with the study procedures.\n* Subject is the Investigator or any Sub-Investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol;\n* Subjects with life expectancy \\< 6 months;\n* Requirement for concomitant treatment that could bias primary evaluation.\n* Subjects who are pregnant or breast-feeding.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Urine Jet Conspicuity Score","description":"The urine jet conspicuity score provided by the blinded central review process as assessed by the following 5-point ordinal scale.\n\n1. = No jet observed\n2. = Weak jet, little color contrast\n3. = Color contrast or significant jet flow\n4. = Strong jet flow with good color contrast\n5. = Strong jet flow with striking contrast in color","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"1.34"},{"groupId":"OG001","value":"4.2","spread":"1.17"},{"groupId":"OG002","value":"2.5","spread":"1.10"}]}]}]},{"type":"SECONDARY","title":"Percentage of Responders","description":"A subject was a responder when there was ≥1-point improvement in the urine jet conspicuity scores following the indigo carmine versus saline treatment (indigo carmine - saline ≥1) and the conspicuity score following the indigo carmine treatment was 3, 4, or 5. The responder criteria were assessed separately for each ureter for each subject based on the blinded central reviewer's conspicuity score.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"41","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Physician Satisfaction Agreement Scale","description":"After the completion of the procedure, the surgeon rated the experience of using indigo carmine for each subject using the 5-point PSAS, in which:\n\n\"Compared to the use of saline treatment, my ability to assess ureteral patency was improved after the addition of indigo carmine.\"\n\n1. = Strongly Agree\n2. = Agree\n3. = Neither Agree nor Disagree\n4. = Disagree\n5. = Strongly Disagree\n\nThe surgeon was considered satisfied with the indigo carmine treatment if his/her rating was either a 1 (strongly agree) or a 2 (agree); otherwise, the surgeon was considered unsatisfied with the indigo carmine treatment.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"38","spread":null}]},{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Visualization","description":"Time to visualization (minutes) of blue color in the ureteral jets flow following indigo carmine treatment","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.00","spread":null},{"groupId":"OG001","value":"5.93","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Surgeon Urine Jet Conspicuity Score","description":"The urine jet conspicuity score provided by the surgeon as assessed by the following 5-point ordinal scale.\n\n1. = No jet observed\n2. = Weak jet, little color contrast\n3. = Color contrast or significant jet flow\n4. = Strong jet flow with good color contrast\n5. = Strong jet flow with striking contrast in color","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":"1.31"},{"groupId":"OG001","value":"4.2","spread":"1.26"},{"groupId":"OG002","value":"2.4","spread":"1.07"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Concordance of Conspicuity Scores","description":"Concordance of conspicuity scores between the surgeons' assessments and the blinded central reviewer assessments. If the difference between raters in conspicuity score was within ±1 (ie, the difference ranged from 1 to +1, inclusive), the scores were considered to agree.\n\nThe urine jet conspicuity score as assessed by the following 5-point ordinal scale.\n\n1. = No jet observed\n2. = Weak jet, little color contrast\n3. = Color contrast or significant jet flow\n4. = Strong jet flow with good color contrast\n5. = Strong jet flow with striking contrast in color","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"38","spread":null},{"groupId":"OG002","value":"67","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"37","spread":null},{"groupId":"OG002","value":"63","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"25","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Conspicuity Score Difference Between the Indigo Carmine High Dose and Indigo Carmine Low Dose by Central Review Process","description":"Exploratory analysis of the urine jet conspicuity score difference between the indigo carmine high dose and indigo carmine low dose by central review Process\n\nThe urine jet conspicuity score provided by the blinded central review process as assessed by the following 5-point ordinal scale.\n\n1. = No jet observed\n2. = Weak jet, little color contrast\n3. = Color contrast or significant jet flow\n4. = Strong jet flow with good color contrast\n5. = Strong jet flow with striking contrast in color","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"1.34"},{"groupId":"OG001","value":"4.2","spread":"1.17"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Conspicuity Score Difference Between the Indigo Carmine High Dose and Indigo Carmine Low Dose as Assessed by Surgeons Who Were Blinded to the Dose of Indigo Carmine","description":"Exploratory analysis of conspicuity score difference between the indigo carmine high dose and indigo carmine low dose as assessed by surgeons who were blinded to the dose of indigo carmine\n\nThe urine jet conspicuity score as assessed by the following 5-point ordinal scale.\n\n1. = No jet observed\n2. = Weak jet, little color contrast\n3. = Color contrast or significant jet flow\n4. = Strong jet flow with good color contrast\n5. = Strong jet flow with striking contrast in color","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":"1.31"},{"groupId":"OG001","value":"4.2","spread":"1.26"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":60},"commonTop":["Constipation","Dysuria","Abdominal pain","Nausea","Pyrexia"]}}}